News
Market and company headlines
BYSIAll
Loading
06:00Oct 131 Story
11:00-16:00Sep 292 Stories
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session.
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC Transcript
BeyondSpring Inc. (BYSI) Discusses FDA Fast Track Designation and Strategic Transaction for Plinabulin in Post-ICI Non-Squamous NSCLC September 29, 2026...
09:00-11:00Sep 292 Stories
BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances
BeyondSpring received FDA Fast Track designation for Plinabulin plus docetaxel in post-ICI non-squamous NSCLC and announced a strategic transaction designed to reduce the cash required to advance its global Phase 3 DUBLIN-4 trial toward a prespecified interim analysis. Key Investor TakeawaysBeyondSpring (NASDAQ:BYSI) received FDA Fast Track designation for Plinabulin plus docetaxel in advanced or metastatic non-squamous NSCLC following prior anti-PD-(L)1 therapy and platinum chemotherapy.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's regular session. The market value of their outstanding shares is at $42.5 million. Iovance Biotherapeutics
07:00Sep 291 Story
09:00Sep 101 Story
09:00Aug 271 Story
13:00-18:00Aug 142 Stories
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy AACR 2026 Preclinical Data Provide the Scientific Rationale for Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC) Regimens to Improve Efficacy, Survival and Tolerability Leadership Transition Effective July 1, 2026 Aligns the Organization Around Focused Advancement of
BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.02) per share. This is a 50 percent increase over losses of $(0.04) per share from the same period last year.